

ASX Release

Newsletter January 2020

PERTH, AUSTRALIA – 20 January 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, has published a newsletter for shareholders.

A copy of the newsletter is available via SUDA's website:

<https://sudapharma.com/investors/media/>

Dr Michael Baker, Chief Executive Officer said: "Newsletters will form part of our communications strategy where we are able to provide further insight into the business. In addition I am looking forward to a very busy 2020, engaging with our shareholders and providing updates over the course of the year."

For and on behalf of the Board and for further information please contact:

Paul Hopper
Executive Chairman
SUDA Pharmaceuticals Ltd
Tel: +61 (0) 406 671 515
phopper@sudapharma.com

Dr Michael Baker
Chief Executive Officer
SUDA Pharmaceuticals Ltd
Tel +61 (0) 403 468 187
mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com